therapeutic autologous dendritic cells
Adcendo Secures $135M for ADC Pipeline Development
Adcendo, ADC pipeline, funding, biotech, cancer treatment, clinical trials
Adcendo Secures $135 Million Funding for Antibody-Drug Conjugate Pipeline
Adcendo, Novo Holdings, ADC pipeline, funding, biotech, antibody-drug conjugate
Pyxis Oncology Faces Setback as Early ADC Readout in Solid Tumors Fails to Impress
Pyxis Oncology, ADC, PYX-201, solid tumors, clinical trial, stock performance
IDEAYA Advances Cancer Pipeline with Biocytogen’s Bispecific ADC, Targeting B7H3/PTK7
IDEAYA, Biocytogen, Bispecific ADC, B7H3/PTK7, Cancer Pipeline, Precision Medicine Oncology
Daiichi Sankyo and Merck Achieve Phase III Success with HER3-Targeted ADC in Lung Cancer
Patritumab deruxtecan, HER3-targeted ADC, Non-small cell lung cancer (NSCLC), Phase III trial, HERTHENA-Lung02, Daiichi Sankyo, Merck & Co.
WCLC24: Merck & Daiichi Sankyo’s ADC Shows Promising Results in Small Cell Lung Cancer
WCLC24, Merck & Co., Daiichi Sankyo, ADC (Antibody Drug Conjugate), SCLC (Small Cell Lung Cancer), Ifinatamab Deruxtecan, DXd ADC Technology
Promising Phase 2 Results for Ifinatamab Deruxtecan in Small Cell Lung Cancer
Ifinatamab Deruxtecan, Small Cell Lung Cancer, Phase 2 Trial, ADC Technology, Daiichi Sankyo, Merck
Duality Biotherapeutics Files for Hong Kong IPO, Expanding ADC Therapeutics Portfolio
Duality Biotherapeutics, Hong Kong IPO, ADC Therapeutics, BioNTech, BeiGene, Cancer Treatment
WuXi Biologics’ ADC Spinout Sees Revenue Surge Amid Biosecure Threat
WuXi Biologics, ADC spinout, revenue jump, Biosecure risk, CRDMO, bioconjugate market
Adcendo Secures $1 Billion Deal for Multitude’s Anti-TF ADC
Adcendo, Multitude Therapeutics, anti-TF ADC, $1 billion deal, biobucks, antibody-drug conjugate, cancer treatment